Core Insights - Microbix Biosystems Inc. and SEKISUI Diagnostics, LLC are collaborating to support the U.S. commercialization of a molecular point-of-care assay for COVID/Flu A/Flu B using the Metrix platform [1][2][3] Company Overview - Microbix Biosystems Inc. specializes in creating proprietary biological products for human health, with revenues of C$ 25.4 million in its latest fiscal year and over 120 skilled employees [6] - SEKISUI Diagnostics, LLC has over 40 years of experience in providing innovative medical diagnostics globally, including clinical chemistry reagents and point-of-care tests [5] Product Details - The Metrix COVID/Flu Test is a 20-minute three-plex molecular assay that accurately detects SARS-COV-2, Influenza A, and Influenza B, showing 95-99% positive and negative concurrence with lab-based molecular assays [2][3] - The test is available in the U.S. under an Emergency-Use Authorization from the U.S. Food and Drug Administration [2] Collaboration and Support - Microbix is supplying SEKISUI with REDx™FLOQ quality assessment products (QAPs) to support the full patient-sample workflow of the Metrix Test, helping to avoid user errors [3][4] - The collaboration aims to enhance user training and compliance with quality systems, which is critical for customer support [4]
Microbix Partners with SEKISUI Diagnostics to Support COVID/Flu Tests